In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S ...

A study by an international team of scientists is raising great hopes for patients suffering from these conditions - Dr.

Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...

When a virus enters the lungs, the immune system has to react fast. The lung maintains its own community of immune cells ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. By acquiring GSK-founded Ouro Medicines, ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Opinion: Thousands of Marylanders are living with sickle cell disease, but our health care system has not kept pace with our ...

Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, ...

Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Effective anti-tumor immunity is not only defined by which immune cells are present in a tumor, but also by how they are organized in space. Across cancer ...

A clinical trial in China testing ICP-538, a treatment candidate for MS and other autoimmune diseases, has dosed its first ...